Abaxis (ABAX) Veterinary Division Announces Development of Quantitative Lyme Test
Tweet
Share
E-mailGet Alerts ABAX Hot Sheet
Join SI Premium – FREE
Abaxis, Inc. (Nasdaq: ABAX) announced its Abaxis Veterinary Reference Laboratories (AVRL) Division, based in Olathe, Kansas, is now offering a quantitative antibody test for canine Lyme disease. The new canine Lyme test invented and developed by Abaxis, Inc., measures a combination of antibodies to peptides which mimic certain antigens of the Borrelia burgdorferi spirochete. These antibodies are not found in vaccinated or non-infected patients.
The new quantitative Lyme test can be used as a standalone diagnostic test to determine infection status or efficacy of treatment. It can also be used as a quantitative confirmation test for the soon to be released VetScan Lyme Rapid Test which is currently under development.
The new quantitative Lyme test can be used as a standalone diagnostic test to determine infection status or efficacy of treatment. It can also be used as a quantitative confirmation test for the soon to be released VetScan Lyme Rapid Test which is currently under development.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boeing names Ryan Shedd as new SVP and controller
- Lazard Global Total Return fund declares $0.1534 monthly distribution
- CoVolt Power files for proposed IPO
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
